Eris Lifesciences’ Board of Directors approved the re-appointment of Mr. Krishnakumar Vaidyanathan as Whole Time Director for five years starting September 1, 2026, and Ms. Kalpana Unadkat as an Independent Director for five years beginning January 5, 2026. The board also reviewed and approved the unaudited standalone and consolidated financial results for Q2 (Jul-Sep) and H1 (Apr-Sep) of FY26. Consolidated revenue stood at ₹792.41 crore for the quarter.
Key Leadership Re-appointments
The Eris Lifesciences board has approved the re-appointment of key personnel:
- Mr. Krishnakumar Vaidyanathan: Re-appointed as Whole Time Director for a term of five years, effective from September 1, 2026, until August 31, 2031.
- Ms. Kalpana Unadkat: Re-appointed as an Independent Director for a term of five years, effective from January 5, 2026, until January 4, 2031.
Financial Highlights: Consolidated Results
The Board reviewed and approved the unaudited consolidated financial results for the second quarter (Q2) and first half (H1) of FY26, with these key highlights:
- Revenue from Operations: ₹792.41 crore for Q2.
- Total Income: ₹795.22 crore for Q2.
- Profit Before Tax: ₹172.67 crore for Q2.
- Net Profit: ₹134.47 crore for Q2.
- Revenue from Operations: ₹1,565.41 crore for H1.
- Total Income: ₹1,570.91 crore for H1.
- Profit Before Tax: ₹333.77 crore for H1.
- Net Profit: ₹259.57 crore for H1.
Financial Highlights: Standalone Results
The Board reviewed and approved the unaudited standalone financial results for the second quarter (Q2) and first half (H1) of FY26, with these key highlights:
- Revenue from Operations: ₹650.50 crore for Q2.
- Total Income: ₹674.09 crore for Q2.
- Profit Before Tax: ₹234.67 crore for Q2.
- Net Profit: ₹149.57 crore for Q2.
- Revenue from Operations: ₹1,229.14 crore for H1.
- Total Income: ₹1,275.41 crore for H1.
- Profit Before Tax: ₹390.93 crore for H1.
- Net Profit: ₹249.56 crore for H1.
Source: BSE
